ZNF621

Across TCGA pan-cancer cohorts, ZNF621 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of ZNF621’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ZNF621 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ZNF621 is over-expressed in tumor, although a few such as THCA and LUSC show the opposite, repressed pattern.

LIHC, COAD, and CHOL are the cancer types where ZNF621 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZNF621 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	All	+0.760	<.001	8	view →
COAD	Male	II,III,IV	+0.528	<.001	8	view →
CHOL	All	All	+1.885	<.001	5	view →
BLCA	All	All	+0.372	.021	5	view →
STAD	All	II,III,IV	+0.634	.005	3	view →
THCA	All	II,III,IV	−0.349	.007	3	view →
HNSC	All	All	+0.247	.022	3	view →
LUSC	All	All	−0.235	.006	3	view →
READ	All	III,IV	+0.929	.010	2	view →
KIRP	Female	All	+0.487	.022	1	view →
KICH	All	All	−0.417	.023	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

ZNF621–LIHC

Open the LIHC breakdown →